SunTrust Robinson Humphrey analyst, Edward Nash, reiterated his Buy rating on shares of Spark Therapeutics (NASDAQ: ONCE) but cut his ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE